Varex Imaging Corporation (VREX) 株式分析

企業概要

Varex Imaging Corporation is a specialized enterprise within the healthcare sector that focuses on the design, manufacturing, and sales of X-ray imaging components for both medical and industrial applications. This positioning within the medical devices industry provides the company with exposure to critical diagnostic infrastructure used across hospitals and imaging centers. The company operates with a substantial operational scale, employing approximately 2,400 individuals to support its global manufacturing and service networks. With a total market capitalization of $462.79M and annual revenue reaching $854.40M over the trailing twelve months, the firm demonstrates a significant presence in its niche market. These valuation and revenue figures indicate that Varex maintains a mature market position capable of generating substantial top-line volume despite operating in a highly competitive environment.

財務健全性

The company reported a total revenue of $854.40M for the trailing twelve months, yet this top-line growth was accompanied by a net income loss of $-67.7M. The disparity between the $854.40M in revenue and the negative net income reveals a cost structure where operating expenses and interest obligations significantly erade pre-tax profits. Despite the net loss, the company posted an EBITDA of $97.20M, suggesting that core operational cash generation remains positive before financing costs. However, the free cash flow stands at $-15.6875M, which indicates a current drain on liquidity that limits immediate financial flexibility for share buybacks or aggressive debt reduction without external capital. The gross margin is 34.2%, reflecting the pricing power and cost efficiency in manufacturing X-ray components, while the operating margin of 7.3% shows moderate overhead control relative to sales. The profit margin of -7.9% confirms that non-operating expenses or interest costs are currently outweighing operating profits. On the balance sheet, total cash of $125.60M is contrasted against total debt of $401.30M, resulting in a debt-to-equity ratio of 81.76. This leverage structure indicates a highly leveraged balance sheet where debt obligations substantially exceed equity capitalization. The current ratio is 3.89, which signifies strong short-term liquidity as current assets are nearly four times greater than current liabilities. Return on equity is -12.9%, indicating that shareholder value is currently being diluted, while return on assets is 3.6%, showing that the asset base is generating minimal positive returns on an absolute basis.

バリュエーション評価

The P/E ratio based on trailing twelve-month earnings is listed as N/A due to the net loss, whereas the forward P/E is 10.48, implying market expectations for future profitability recovery. The price-to-book ratio is 0.97, indicating that the market values the company at roughly equal to its book value rather than at a significant premium. The price-to-sales ratio is 0.54, and the EV/EBITDA stands at 7.74, suggesting the market is pricing the stock conservatively relative to its sales and earnings potential. The stock has a 52-week high of $14.56 and a 52-week low of $6.76, meaning the current trading price sits within this historical range but requires specific calculation to determine the exact percentage deviation from the high or low at any given moment. The beta is 1.00, which indicates that the stock's price volatility mirrors the broader market movements without exhibiting amplified or dampened sensitivity to market fluctuations.

Growth & Income

Revenue growth over the last year was 4.9%, while earnings growth is N/A due to the reported net loss for the trailing period. Since earnings are currently negative, it is impossible to determine if they are growing faster or slower than revenue in the traditional sense, but the positive revenue growth suggests expanding market share or successful pricing strategies. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its earnings and operational cash flow into growth initiatives, R&D, or debt servicing rather than distributing income to shareholders. This non-dividend strategy aligns with a growth-focused profile where capital retention is prioritized over current income generation for investors seeking capital appreciation.